Fosfosal | CAS#6064-83-1 | analgesic

MedKoo Cat#: 461719 | Name: Fosfosal

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fosfosal is a non-acetylated salicylic acid derivative that acts as an anti-inflammatory analgesic drug.

Chemical Structure

Fosfosal

CAS#6064-83-1

Theoretical Analysis

MedKoo Cat#: 461719

Name: Fosfosal

CAS#: 6064-83-1

Chemical Formula: C7H7O6P

Exact Mass: 217.9980

Molecular Weight: 218.10

Elemental Analysis: C, 38.55; H, 3.24; O, 44.01; P, 14.20

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Fosfosal; Disdolen; Fosfosalum; Phosphonoxybenzoic acid; Salicyl phosphate; UR 1521; UR-1521; UR1521; UR 1522; UR-1522; UR1522;

IUPAC/Chemical Name

2-(phosphonooxy)benzoic acid

InChi Key

FFKUDWZICMJVPA-UHFFFAOYSA-N

InChi Code

InChI=1S/C7H7O6P/c8-7(9)5-3-1-2-4-6(5)13-14(10,11)12/h1-4H,(H,8,9)(H2,10,11,12)

SMILES Code

O=C(O)C1=CC=CC=C1OP(O)(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 218.10 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Méndez JA, Fernández M, González-Corchón A, Salvado M, Collía F, de Pedro JA, Levenfeld BL, López-Bravo A, Vázquez B, San Román J. Injectable self-curing bioactive acrylic-glass composites charged with specific anti-inflammatory/analgesic agent. Biomaterials. 2004 May;25(12):2381-92. PubMed PMID: 14741603. 2: Gómez LA, Ramis J, Julve J, García-Rafanell J, Forn J. The effect of fosfosal and acetylsalicylic acid on leukocyte migration and PGE2 concentration in experimentally induced acute inflammation. Eur J Pharmacol. 1988 Mar 15;147(3):459-63. PubMed PMID: 3163974. 3: Ramis J, Torrent J, Mis R, Barbanoj M, Abadias M, Jane F, Forn J. Pharmacokinetics of fosfosal after single and multiple oral doses in man. Int J Clin Pharmacol Ther Toxicol. 1988 Sep;26(9):421-7. PubMed PMID: 3264273. 4: Ramis J, Mis R, Forn J. Pharmacokinetics of fosfosal in rats and dogs. Arzneimittelforschung. 1989 Jan;39(1):74-7. PubMed PMID: 2719746. 5: Delgadillo Duarte J, Videla Ces S, Navas Ramírez J, Oltra Juste J. [Fosfosal-induced hepatitis]. Rev Clin Esp. 1994 Mar;194(3):203-4. Spanish. PubMed PMID: 8008964. 6: Caballería Rovira E. [Toxic hepatitis due to fosfosal]. Rev Clin Esp. 1993 Feb;192(3):148. Spanish. PubMed PMID: 8465053. 7: Diaz C, Gassó FC, Panadés JN. Double-blind study of the analgesic activity of fosfosal in patients with musculoskeletal and articular pain: comparison with lysine acetylsalicylate and placebo. Clin Ther. 1981;4(2):121-6. PubMed PMID: 6794911. 8: Ramis J, Gich I, Torrent J, Mis R, Jané F, Forn J. Bioavailability study of fosfosal and codeine administered alone or in combination. Int J Clin Pharmacol Ther Toxicol. 1989 Jul;27(7):352-7. PubMed PMID: 2777424. 9: Rafanell JG, Bellés L, Sánchez MS, Forn J. Pharmacological study of 2-phosphonoxybenzoic acid (fosfosal), a new analgesic drug. Arzneimittelforschung. 1980;30(7):1091-8. PubMed PMID: 6251858. 10: Madera Cat L, García Rafanell JM. [Comparative double-blind study of the analgesic activity of fosfosal (UR-1521) in patients with musculoskeletal and articular pain (author's transl)]. Med Clin (Barc). 1981 Jan 10;76(1):18-22. Spanish. PubMed PMID: 7012470. 11: García Rafanell J, Bellés L, Sánchez MS, Forn J. [Pharmacological and biochemical study of a new non-narcotic analgesic: fosfosal (UR-1521)]. Arch Farmacol Toxicol. 1981 Apr;7(1):13-24. Spanish. PubMed PMID: 6976776. 12: Gräber M, Janczyk W, Sperl B, Elumalai N, Kozany C, Hausch F, Holak TA, Berg T. Selective targeting of disease-relevant protein binding domains by O-phosphorylated natural product derivatives. ACS Chem Biol. 2011 Oct 21;6(10):1008-14. doi: 10.1021/cb2001796. Epub 2011 Aug 10. PubMed PMID: 21797253. 13: González Corchón MA, Salvado M, de la Torre BJ, Collía F, de Pedro JA, Vázquez B, Román JS. Injectable and self-curing composites of acrylic/bioactive glass and drug systems. A histomorphometric analysis of the behaviour in rabbits. Biomaterials. 2006 Mar;27(9):1778-87. Epub 2005 Nov 2. PubMed PMID: 16260032. 14: Sánchez MS, Bellés L, Garcia Rafanell J, Forn J. Acute, subacute and chronic toxicity of fosfosal. Arzneimittelforschung. 1980;30(7):1098-101. PubMed PMID: 6968216. 15: Rimbau V, López R, Fernández A, Forn J. [Distribution and pharmacokinetics of fosfosal (UR-1521)]. Arch Farmacol Toxicol. 1981 Apr;7(1):61-4. Spanish. PubMed PMID: 7325717. 16: Isozaki Y, Hoshino I, Akutsu Y, Hanari N, Mori M, Nishimori T, Murakami K, Akanuma N, Toyozumi T, Takahashi M, Suito H, Takeshita N, Maruyama T, Suzuki A, Nakayama T, Matsubara H. Screening of alternative drugs to the tumor suppressor miR-375 in esophageal squamous cell carcinoma using the connectivity map. Oncology. 2014;87(6):351-63. doi: 10.1159/000365592. Epub 2014 Sep 5. PubMed PMID: 25195536. 17: Roig MG, Burguillo FJ, Del Arco A, Usero JL, Izquierdo C, Herraez MA. Kinetic studies of the transphosphorylation reactions catalyzed by alkaline phosphatase from E. coli: hydrolysis of p-nitrophenyl phosphate and o-carboxyphenyl phosphate in presence of Tris. Int J Biochem. 1982;14(7):655-66. PubMed PMID: 7049787. 18: Sánchez MS, García Rafanell J, Forn J. [Comparative study of the in vitro anti-aggregating action of various salicylic derivatives]. Arch Farmacol Toxicol. 1981 Apr;7(1):89-92. Spanish. PubMed PMID: 7325722. 19: Martinez MB, Flickinger MC, Nelsestuen GL. Accurate kinetic modeling of alkaline phosphatase in the Escherichia coli periplasm: implications for enzyme properties and substrate diffusion. Biochemistry. 1996 Jan 30;35(4):1179-86. PubMed PMID: 8573572. 20: Herraez HA, Burguillo FJ, Roig MG, Usero JL. Phosphoryl transfer from o-carboxyphenyl phosphate to tri(hydroxymethyl)-aminomethane catalysed by alkaline phosphatase from E. coli. Int J Biochem. 1980;11(6):511-8. PubMed PMID: 6991307.